Skip to main content

Table 1 Summarized overview of global innovation activities on drug development in pharmaceutical companies (July 2016 – June 2019)

From: Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study

  All pharmaceutical companies (Number of drugs, (%)) Top 20 leading companies (Number of drugs, (%)) Percentage of top 20 companies
Total 10,550 (100) 2669 (100) 25.3%
Phase
 Discovery 1406 (13.3) 260 (9.7) 18.5%
 Preclinical 2979 (28.2) 275 (10.3) 9.2%
 Clinicals 144 (1.4) 7 (0.3) 4.9%
 Phase I 1794 (17) 523 (19.6) 29.2%
 Phase II 1936 (18.4) 482 (18.1) 24.9%
 Phase III 817 (7.7) 230 (8.6) 28.2%
 Pre-registration 168 (1.6) 46 (1.7) 27.4%
 Registered 146 (1.4) 37 (1.4) 25.3%
 Marketed 1070 (10.1) 754 (28.3) 70.5%
 N/A (Technology) 90 (0.9) 55 (2.1) 61.1%
Orphan drugsa 1076 (10.2) 355 (13.3) 33.0%
Biologic productsb 4905 (46.5) 1165 (43.6) 23.8%
  1. a Drugs being developed for rare diseases and have been designated as orphan drugs
  2. b Drugs being developed as biologic therapies